NRx Pharmaceuticals (NRXP)
Develops NMDA-pathway CNS therapies alongside a majority-owned interventional-psychiatry clinic network.
Something off on this page? Send us feedback.
Develops NRX-100 and NRX-101, two CNS drug candidates targeting the NMDA pathway. Through its majority-owned HOPE Therapeutics network, it also provides interventional psychiatric care integrating neuroplastic drugs, TMS, digital therapeutics, and hyperbaric therapy.
Develops the NRX-100 and NRX-101 CNS drug candidates, based on the NMDA pathway. NRX-100 is a preservative-free intravenous ketamine formulation, and NRX-101 combines oral D-cycloserine with lurasidone. Both programs remain in development, rather than approved products.
HOPE Therapeutics supplies a care-delivery arm alongside NeuroRx's pharmaceutical-development work. The majority-owned network delivers interventional psychiatric care through neuroplastic drugs, TMS, digital therapeutics, and hyperbaric therapy, with clinics in Florida. The listed public issuer arose from a NeuroRx/SPAC merger.
Drug candidates require regulatory progress, while the newer clinic network depends on early care-delivery execution.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $26.7M · Total debt $1.2M · Total assets $34.2M · Shareholders' equity −$170.0K
- Revenue
- $1.1M
- Operating income
- −$6.5M
- Net income
- −$16.5M
No dividends on record.
| Institutions38 holders · as of Mar 31, 2026 | 35.90% | 6.20M shares | |
| Insiders1 holder · as of Dec 18, 2024 | 0.49% | 84.6K shares | |
| Strategic holders1 holder · as of May 26, 2021 | 0.38% | 65.6K shares | |
| Otherremainder | 63.23% | 10.93M shares |
17.29M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (43.30M in the company's Sep 3, 2026 report, 17.29M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
B Group, Inc.Institution | 17.36% | 3.00M | 13Fas of Mar 31, 2026 |
Anson Funds Management LPInstitution | 9.28% | 1.60M | 13Gfiled Aug 14, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 6.71% | 1.16M | 13Fas of Mar 31, 2026 |
Advisorshares Investments LLCInstitution | 2.43% | 420,467 | 13Fas of Mar 31, 2026 |
Commonwealth Equity Services, LLCInstitution | 2.30% | 397,431 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Johnson & Johnson
Esketamine treatment for treatment-resistant and acute-suicidality depression
- Neuronetics
TMS systems and Greenbrook clinics for depression care
- AbbVie
Oral cariprazine therapy for bipolar depression and adjunctive MDD
- Axsome Therapeutics
Rapid-acting oral NMDA therapy for major depressive disorder
- Atai Beckley
Psychedelic medicines in development for treatment-resistant depression
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NRx Pharmaceuticals | $3.38 | −2.16% | $59.8M | — | — | 17.6 | — |
| Johnson & Johnson | $275.35 | +0.04% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Neuronetics | $2.71 | −2.17% | $192.8M | — | — | 1.2 | +9.1% |
| AbbVie | $264.00 | +0.88% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Axsome Therapeutics | $212.18 | +1.08% | $10.80B | — | 1,800.7 | 13.9 | +44.2% |
| Atai Beckley | $7.32 | −0.39% | $2.72B | — | — | 607.9 | +137.0% |
| Median | 52.8 | 23.1 | 7.2 | +10.2% |